Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin

Robert A Brodsky, G. L. Mukhina, S. Li, K. L. Nelson, P. L. Chiurazzi, J. T. Buckley, Michael J Borowitz

Research output: Contribution to journalArticle

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a somatic mutation in the gene PIGA, which encodes an enzyme essential for the synthesis of glycosylphosphatidylinositol (GPI) anchors. The PIGA mutation results in absence or marked deficiency of more than a dozen proteins on PNH blood cells. Current flow cytometric assays for PNH rely on the use of labeled antibodies to detect deficiencies of specific GPI anchor proteins, such as CD59. However, because no single GPI anchor protein is always expressed in all cell lineages, no one monoclonal antibody can be used with confidence to diagnose PNH. We describe a new diagnostic test for PNH, based on the ability of a fluorescently labeled inactive variant of the protein aerolysin (FLAER) to bind selectively to GPI anchors. We compared GPI anchor protein expression in 8 patients with PNH using FLAER and anti-CD59. In all cases, FLAER detected similar or higher proportions of PNH monocytes and granulocytes compared with anti-CD59. Because of the increased sensitivity of detection, FLAER could detect small abnormal granulocyte populations in patients to a level of about 0.5%; samples from healthy control subjects contained substantially fewer FLAER-negative cells. FLAER gives a more accurate assessment of the GPI anchor deficit in PNH.

Original languageEnglish (US)
Pages (from-to)459-466
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume114
Issue number3
StatePublished - 2000

Fingerprint

Paroxysmal Hemoglobinuria
Glycosylphosphatidylinositols
Proteins
Granulocytes
Mutation
aerolysin
Cell Lineage
Routine Diagnostic Tests
Monocytes
Blood Cells
Healthy Volunteers
Monoclonal Antibodies
Antibodies

Keywords

  • Aerolysin
  • Aplastic anemia
  • CD59
  • GPI anchor proteins
  • Paroxysmal nocturnal hemoglobinuria

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. / Brodsky, Robert A; Mukhina, G. L.; Li, S.; Nelson, K. L.; Chiurazzi, P. L.; Buckley, J. T.; Borowitz, Michael J.

In: American Journal of Clinical Pathology, Vol. 114, No. 3, 2000, p. 459-466.

Research output: Contribution to journalArticle

Brodsky, Robert A ; Mukhina, G. L. ; Li, S. ; Nelson, K. L. ; Chiurazzi, P. L. ; Buckley, J. T. ; Borowitz, Michael J. / Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. In: American Journal of Clinical Pathology. 2000 ; Vol. 114, No. 3. pp. 459-466.
@article{56c049488449499283a7148d732dfa09,
title = "Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin",
abstract = "Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a somatic mutation in the gene PIGA, which encodes an enzyme essential for the synthesis of glycosylphosphatidylinositol (GPI) anchors. The PIGA mutation results in absence or marked deficiency of more than a dozen proteins on PNH blood cells. Current flow cytometric assays for PNH rely on the use of labeled antibodies to detect deficiencies of specific GPI anchor proteins, such as CD59. However, because no single GPI anchor protein is always expressed in all cell lineages, no one monoclonal antibody can be used with confidence to diagnose PNH. We describe a new diagnostic test for PNH, based on the ability of a fluorescently labeled inactive variant of the protein aerolysin (FLAER) to bind selectively to GPI anchors. We compared GPI anchor protein expression in 8 patients with PNH using FLAER and anti-CD59. In all cases, FLAER detected similar or higher proportions of PNH monocytes and granulocytes compared with anti-CD59. Because of the increased sensitivity of detection, FLAER could detect small abnormal granulocyte populations in patients to a level of about 0.5{\%}; samples from healthy control subjects contained substantially fewer FLAER-negative cells. FLAER gives a more accurate assessment of the GPI anchor deficit in PNH.",
keywords = "Aerolysin, Aplastic anemia, CD59, GPI anchor proteins, Paroxysmal nocturnal hemoglobinuria",
author = "Brodsky, {Robert A} and Mukhina, {G. L.} and S. Li and Nelson, {K. L.} and Chiurazzi, {P. L.} and Buckley, {J. T.} and Borowitz, {Michael J}",
year = "2000",
language = "English (US)",
volume = "114",
pages = "459--466",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin

AU - Brodsky, Robert A

AU - Mukhina, G. L.

AU - Li, S.

AU - Nelson, K. L.

AU - Chiurazzi, P. L.

AU - Buckley, J. T.

AU - Borowitz, Michael J

PY - 2000

Y1 - 2000

N2 - Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a somatic mutation in the gene PIGA, which encodes an enzyme essential for the synthesis of glycosylphosphatidylinositol (GPI) anchors. The PIGA mutation results in absence or marked deficiency of more than a dozen proteins on PNH blood cells. Current flow cytometric assays for PNH rely on the use of labeled antibodies to detect deficiencies of specific GPI anchor proteins, such as CD59. However, because no single GPI anchor protein is always expressed in all cell lineages, no one monoclonal antibody can be used with confidence to diagnose PNH. We describe a new diagnostic test for PNH, based on the ability of a fluorescently labeled inactive variant of the protein aerolysin (FLAER) to bind selectively to GPI anchors. We compared GPI anchor protein expression in 8 patients with PNH using FLAER and anti-CD59. In all cases, FLAER detected similar or higher proportions of PNH monocytes and granulocytes compared with anti-CD59. Because of the increased sensitivity of detection, FLAER could detect small abnormal granulocyte populations in patients to a level of about 0.5%; samples from healthy control subjects contained substantially fewer FLAER-negative cells. FLAER gives a more accurate assessment of the GPI anchor deficit in PNH.

AB - Paroxysmal nocturnal hemoglobinuria (PNH) is caused by a somatic mutation in the gene PIGA, which encodes an enzyme essential for the synthesis of glycosylphosphatidylinositol (GPI) anchors. The PIGA mutation results in absence or marked deficiency of more than a dozen proteins on PNH blood cells. Current flow cytometric assays for PNH rely on the use of labeled antibodies to detect deficiencies of specific GPI anchor proteins, such as CD59. However, because no single GPI anchor protein is always expressed in all cell lineages, no one monoclonal antibody can be used with confidence to diagnose PNH. We describe a new diagnostic test for PNH, based on the ability of a fluorescently labeled inactive variant of the protein aerolysin (FLAER) to bind selectively to GPI anchors. We compared GPI anchor protein expression in 8 patients with PNH using FLAER and anti-CD59. In all cases, FLAER detected similar or higher proportions of PNH monocytes and granulocytes compared with anti-CD59. Because of the increased sensitivity of detection, FLAER could detect small abnormal granulocyte populations in patients to a level of about 0.5%; samples from healthy control subjects contained substantially fewer FLAER-negative cells. FLAER gives a more accurate assessment of the GPI anchor deficit in PNH.

KW - Aerolysin

KW - Aplastic anemia

KW - CD59

KW - GPI anchor proteins

KW - Paroxysmal nocturnal hemoglobinuria

UR - http://www.scopus.com/inward/record.url?scp=0034502010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034502010&partnerID=8YFLogxK

M3 - Article

C2 - 10989647

AN - SCOPUS:0034502010

VL - 114

SP - 459

EP - 466

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -